{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:39Z","timestamp":1786986939731,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.09.007","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:33:30Z","timestamp":1695922410000},"page":"105-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed\/Refractory Follicular Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Francesc","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Di","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-2880","authenticated-orcid":false,"given":"Marie-Helene Blanchet","family":"Zumofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.09.007_bib0001","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.clml.2023.09.007_bib0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clml.2023.09.007_bib0005","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study","volume":"9","author":"Casulo","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.09.007_bib0006","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0007","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0008","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0009","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/CMAR.S201024","article-title":"Copanlisib in the treatment of relapsed follicular lymphoma: utility and experience from the clinic","volume":"13","author":"Chauhan","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2023.09.007_bib0010","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(22)00200-5","article-title":"The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0012","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2021.39.15_suppl.7508","article-title":"Efficacy and safety of tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: primary analysis of the phase 2 ELARA trial","volume":"31","author":"Schuster","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0013","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0014","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0015","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma. Accessed February 2, 2023."},{"key":"10.1016\/j.clml.2023.09.007_bib0016","unstructured":"European Medicines Agency. Lunsumio [summary of product characteristics]. Roche Pharma AG. 2022."},{"key":"10.1016\/j.clml.2023.09.007_bib0017","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.clml.2023.09.007_bib0018","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0019","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2023.09.007_bib0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clml.2023.09.007_bib0021","series-title":"NICE DSU Technical Support Document 17: the use of observational data to inform estimates of treatment effectiveness for technology appraisal: methods for comparative individual patient data","author":"Faria","year":"2015"},{"key":"10.1016\/j.clml.2023.09.007_bib0022","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1002\/sim.6276","article-title":"The use of bootstrapping when using propensity-score matching without replacement: a simulation study","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0034","first-page":"40","article-title":"Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (AXI-CEL) in patients with relapsed\/refractory (R\/R) indolent non-hodgkin lymphoma (INHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.007_bib0041","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed\/refractory indolent non-Hodgkin lymphoma (R\/R iNHL)","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2021-148473","article-title":"Long-term follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0043","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2021-147608","article-title":"A comparison of clinical outcomes from updated ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed\/refractory follicular lymphoma (R\/R FL)","volume":"138","author":"Palomba","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0057","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0044","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2021-147781","article-title":"Comparison of clinical outcomes among patients with relapsed\/refractory follicular lymphoma treated with tisagenlecleucel in the ELARA trial versus a real-world external control arm of patients treated with standard of care","volume":"138","author":"Hao","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0045","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/blood-2021-149327","article-title":"Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma","volume":"138","author":"Salles","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0046","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2021-145025","article-title":"Efficacy of tisagenlecleucel in adult patients with high-risk relapsed\/refractory follicular lymphoma: subgroup analysis of the phase II ELARA study","volume":"138","author":"Thieblemont","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0047","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0048","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2021-145741","article-title":"Assessment of healthcare resource utilization and costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results from the ELARA study","volume":"138","author":"Fowler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0033","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.14665","article-title":"Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma","volume":"181","author":"Eyre","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.09.007_bib0049","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood-2016-12-757740","article-title":"Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy","volume":"129","author":"Gopal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0050","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.09.007_bib0063","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/10428194.2020.1855344","article-title":"Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas","volume":"62","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.09.007_bib0058","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0051","series-title":"Copiktra Assessment Report (EPAR)","year":"2021"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0052","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-134851","article-title":"Umbralisib, the once daily dual inhibitor of PI3K\u03b4 and casein kinase-1\u03b5 demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 2 global Unity-NHL trial","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0053","series-title":"Revlimid Assessment Report (EPAR)","year":"2022"},{"key":"10.1016\/j.clml.2023.09.007_bib0054","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hon.75_2629","article-title":"AUGMENT phase III study: lenalidomide\/rituximab (R2) improved efficacy over rituximab\/placebo in relapsed\/refractory follicular patients irrespective of POD24 status","volume":"37","author":"Leonard","year":"2019","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.007_bib0064","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137245","article-title":"Analyzing efficacy outcomes from the phase 2 study of single-agent tazemetostat as third-line therapy in patients with relapsed or refractory follicular lymphoma to identify predictors of response","volume":"136","author":"Salles","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0023","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0024","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.clml.2023.09.007_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1198\/106186006X137047","article-title":"Optimal full matching and related designs via network flows","volume":"15","author":"Hansen","year":"2006","journal-title":"J Comput Graph Stat"},{"key":"10.1016\/j.clml.2023.09.007_bib0026","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1162\/REST_a_00318","article-title":"Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies","volume":"95","author":"Diamond","year":"2013","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.clml.2023.09.007_bib0027","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1002\/sim.6602","article-title":"Optimal full matching for survival outcomes: a method that merits more widespread use","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0028","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0029","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","article-title":"Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research","volume":"66","author":"Stuart","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2023.09.007_bib0030","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/sim.2781","article-title":"The performance of different propensity score methods for estimating marginal odds ratios","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2023.09.007_bib0031","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1177\/0962280215601134","article-title":"Estimating the effect of treatment on binary outcomes using full matching on the propensity score","volume":"26","author":"Austin","year":"2017","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.clml.2023.09.007_bib0032","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2021.39.15_suppl.7508","article-title":"Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed\/refractory follicular lymphoma (r\/r FL): primary analysis of the phase 2 Elara trial","volume":"39","author":"Schuster","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0036","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0037","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.007_bib0038","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","article-title":"Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL","volume":"36","author":"Sehn","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.09.007_bib0039","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0040","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.007_bib0055","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1007\/s12325-022-02054-z","volume":"39","author":"Proudman","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2023.09.007_bib0056","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S2666-6367(22)00238-X","article-title":"Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel in relapsed\/refractory follicular lymphoma","volume":"28","author":"Dickinson","year":"2022","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:28Z","timestamp":1761871408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021298"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed\/Refractory Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}